SML4051

ML-T7

Name: ML-T7
Brand: SIGMA

≥98% (HPLC)

别名:

5-(2,4-Dichlorophenyl)-3-(p-tolyl)-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2′-indene]-1′,3′,4,6(3H,5H)-tetraone, 5-(2,4-Dichlorophenyl)-1-(4-methylphenyl)-3a,6a-dihydrosprio[1H-furo[3,4-c]pyrrole-3,20-(10H)-indene]-10,30,4,6(20H,3H,5H)-tetrone

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:

C₂₇H₁₇Cl₂NO₅

化学文摘社编号:

459789-75-4

分子量:

506.33

UNSPSC代码:

12352200

主要文件

查看所有文档

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

生化/生理作用

ML-T7 is a selective T-cell immunoglobulin and mucin domain-containing proteins TIM-3/4 inhibitor that targets the FG-CC′ cleft involved in PtdSer and CEACAM1 binding (h/mTIM-3 Kd = 6.98/7.40 μM, hTIM-4 Kd = 11.98 μM). ML-T7 promotes the activity of nature killer (NK) cells, the antigen-presenting capacity of dendric cells (DCs), the survival and antitumor activity of primary CD8+ cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells (5-10 μM). ML-T7 exerts antitumor activity and potentiates anti-PD-1 therapy in a spontaneous orthotopic hepatocellular carcinoma (HCC) model in mice in vivo (20 mg/kg, q.o.d. i.p.).